Tyloxapol_NN
inhibits_VBZ
NF-kappa_NN
B_NN
and_CC
cytokine_NN
release_NN
,_,
scavenges_VBZ
HOCI_NN
,_,
and_CC
reduces_VBZ
viscosity_NN
of_IN
cystic_JJ
fibrosis_NN
sputum_NN
._.

Cystic_JJ
fibrosis_NN
-LRB-_-LRB-
CF_NN
-RRB-_-RRB-
patients_NNS
develop_VBP
progressive_JJ
cytokine-mediated_JJ
inflammatory_JJ
lung_NN
disease_NN
,_,
with_IN
abundant_JJ
production_NN
of_IN
thick_JJ
,_,
tenacious_JJ
,_,
protease_NN
-_:
and_CC
oxidant-rich_JJ
purulent_JJ
airway_NN
secretions_NNS
that_WDT
are_VBP
difficult_JJ
to_TO
clear_VB
even_RB
with_IN
physiotherapy_NN
._.

In_IN
the_DT
search_NN
for_IN
a_DT
potential_JJ
treatment_NN
,_,
we_PRP
have_VBP
tested_VBN
tyloxapol_NN
,_,
an_DT
alkylaryl_NN
polyether_JJ
alcohol_NN
polymer_NN
detergent_NN
previously_RB
used_VBN
as_IN
a_DT
mucolytic_JJ
agent_NN
in_IN
adult_JJ
chronic_JJ
bronchitis_NN
._.

Tyloxapol_NN
inhibits_VBZ
activation_NN
of_IN
the_DT
transcription_NN
factor_NN
nuclear_JJ
factor-kappa_NN
B_NN
-LRB-_-LRB-
NK-kappa_NN
B_NN
-RRB-_-RRB-
,_,
reduces_VBZ
resting_VBG
secretion_NN
of_IN
the_DT
cytokine_NN
interleukin-8_NN
-LRB-_-LRB-
IL-8_NN
-RRB-_-RRB-
in_IN
cultured_VBN
human_JJ
monocytes_NNS
,_,
and_CC
inhibits_VBZ
lipopolysaccharide_NN
-LRB-_-LRB-
LPS_NN
-RRB-_-RRB-
-_:
stimulated_JJ
release_NN
of_IN
tumor_NN
necrosis_NN
factor-alpha_NN
-LRB-_-LRB-
TNF-alpha_NN
-RRB-_-RRB-
,_,
IL-1_NN
beta_NN
,_,
IL-6_NN
,_,
IL-8_NN
,_,
granulocyte-macrophage_JJ
colony-stimulating_JJ
factor_NN
-LRB-_-LRB-
GM-CSF_NN
-RRB-_-RRB-
,_,
and_CC
the_DT
eiconsanoids_JJ
thromboxane_NN
A2_NN
and_CC
leukotriene_NN
B4_NN
-LRB-_-LRB-
LTB4_NN
-RRB-_-RRB-
._.

We_PRP
have_VBP
previously_RB
shown_VBN
that_IN
tyloxapol_NN
is_VBZ
a_DT
potent_JJ
antioxidant_NN
for_IN
hydroxyl_NN
radicals_NNS
-LRB-_-LRB-
OH_NN
-RRB-_-RRB-
._.

Tyloxapol_NN
-LRB-_-LRB-
0.05_CD
to_TO
0.1_CD
%_NN
wt\/vol_NN
-RRB-_-RRB-
effectively_RB
scavenges_VBZ
the_DT
oxidant_JJ
hypochlorous_JJ
acid_NN
-LRB-_-LRB-
HOCl_NN
;_:
1_CD
to_TO
7.5_CD
mM_NN
-RRB-_-RRB-
in_FW
vitro_FW
,_,
and_CC
protects_VBZ
from_IN
HOCl-mediated_JJ
lung_NN
injury_NN
in_IN
rats_NNS
._.

Tyloxapol_NN
also_RB
reduces_VBZ
the_DT
viscosity_NN
of_IN
CF_NN
sputum_NN
-LRB-_-LRB-
from_IN
463_CD
+_CC
\/_CD
-_:
133_CD
to_TO
128_CD
+_CC
\/_JJ
-_:
52_CD
centipoise_NN
-RRB-_-RRB-
._.

We_PRP
conclude_VBP
that_IN
tyloxapol_NN
is_VBZ
potentially_RB
useful_JJ
as_IN
a_DT
new_JJ
antiinflammatory_JJ
therapy_NN
for_IN
CF_NN
lung_NN
disease_NN
,_,
and_CC
could_MD
possibly_RB
promote_VB
clearance_NN
of_IN
secretions_NNS
in_IN
the_DT
CF_NN
airway_NN
._.

